Evaluation of antitumour and antiinflammatory effects and acute toxicity of extracts obtained from Streptomyces spp. isolated from m Soils of Paraiba (Brazil)

Bioactive metabolites produced by Streptomyces spp. commonly exhibit a variety of pharmacological properties such as antibiotic, antitumor, enzymatic and anti-helminthic. The study evaluated the possible antitumor and anti-inflammatory effects and the degree of toxicity of extracts isolated from Streptomyces in experimental models with animals. The extracts Sp-1 and Sp-3 did not have anti-inflammatory effect. In the Sarcoma 180 model the effects of Sp-1 and Sp-3 were significant with decreased average weights of tumors at 10 mg/kg, and reduction of up to 73 % of initial weight of the implanted tumor. For tumors of Ehrlich Carcinoma, the doses showed no significant effect on the average weight of tumors. Stimulant effects, such as exophthalmia, agitation, escape reaction, irritability, tremors and dermatitis were observed after 1 h of administration, depressive reactions were also observed, such as prostration and decreased respiratory rate, and no deaths were highlighted.Colegio de Farmacéuticos de la Provincia de Buenos Aire

Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)

BACKGROUND: Hypertriglyceridemia in combination with low HDL cholesterol levels is a risk factor for cardiovascular disease. Our objective was to evaluate the efficacy of ciprofibrate for the treatment of this form of dyslipidemia and to identify factors associated with better treatment response. METHODS: Multicenter, international, open-label study. Four hundred and thirty seven patients were included. The plasma lipid levels at inclusion were fasting triglyceride concentrations between 1.6–3.9 mM/l and HDL cholesterol ≤ 1.05 mM/l for women and ≤ 0.9 mM/l for men. The LDL cholesterol was below 4.2 mM/l. All patients received ciprofibrate 100 mg/d. Efficacy and safety parameters were assessed at baseline and at the end of the treatment. The primary efficacy parameter of the study was percentage change in triglycerides from baseline. RESULTS: After 4 months, plasma triglyceride concentrations were decreased by 44% (p < 0.001). HDL cholesterol concentrations were increased by 10% (p < 0.001). Non-HDL cholesterol was decreased by 19%. A greater HDL cholesterol response was observed in lean patients (body mass index < 25 kg/m(2)) compared to the rest of the population (8.2 vs 19.7%, p < 0.001). In contrast, cases with excess body weight had a larger decrease in non-HDL cholesterol levels (-20.8 vs -10.8%, p < 0.001). There were no significant complications resulting from treatment with ciprofibrate. CONCLUSIONS: Ciprofibrate is efficacious for the correction of hypertriglyceridemia / low HDL cholesterol. A greater decrease in non-HDL cholesterol was found among cases with excess body weight. The mechanism of action of ciprofibrate may be influenced by the pathophysiology of the disorder being treated